The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care.

BACKGROUND: Depressive and anxiety disorders commonly occur together in patients presenting in the primary care setting. Although recognition of individual depressive and anxiety disorders has increased substantially in the past decade, recognition of comorbidity still lags. The current report reviews the epidemiology, clinical implications, and management of comorbidity in the primary care setting. METHOD: Literature was reviewed by 2 methods: (1) a MEDLINE search (1980-2001) using the key words depression, depressivedisorders, and anxietydisorders; comorbidity was also searched with individual anxiety diagnoses; and (2) direct search of psychiatry, primary care, and internal medicine journals over the past 5 years. RESULTS: Between 10% and 20% of adults in any given 12-month period will visit their primary care physician during an anxiety or depressive disorder episode (although typically for a nonpsychiatric complaint); more than 50% of these patients suffer from a comorbid second depressive or anxiety disorder. The presence of depressive/anxiety comorbidity substantially increases medical utilization and is associated with greater chronicity, slower recovery, increased rates of recurrence, and greater psychosocial disability. Typically, long-term treatment is indicated, although far less research is available to guide treatment decisions. Selective serotonin reuptake inhibitor antidepressants are the preferred treatment based on efficacy, safety, and tolerability criteria. Knowledge of their differential clinical and pharmacokinetic profiles can assist in optimizing treatment. CONCLUSION: Increased recognition of the high prevalence and negative psychosocial impact of depression and anxiety disorder comorbidity will lead to more effective treatment. While it is hoped that early and effective intervention will yield long-term benefits, research is needed to confirm this.

[1]  S. Preskorn,et al.  Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors , 1997, Clinical Pharmacokinetics.

[2]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[3]  M. Olfson,et al.  Mental disorders and disability among patients in a primary care group practice. , 1997, The American journal of psychiatry.

[4]  N Sartorius,et al.  Depression Comorbid with Anxiety: Results from the WHO Study on Psychological Disorders in Primary Health Care , 1996, British Journal of Psychiatry.

[5]  P. Shapiro,et al.  Depression and the course of coronary artery disease. , 1998, The American journal of psychiatry.

[6]  J. Lépine,et al.  Suicide attempts in patients with panic disorder. , 1993, Archives of general psychiatry.

[7]  R. Kessler,et al.  Comorbidity of DSM–III–R Major Depressive Disorder in the General Population: Results from the US National Comorbidity Survey , 1996, British Journal of Psychiatry.

[8]  D. C. Olivier,et al.  Prodromes of Depression and Anxiety , 1989, British Journal of Psychiatry.

[9]  R. Carney,et al.  Depression and poor glycemic control: a meta-analytic review of the literature. , 2000, Diabetes care.

[10]  J. Mitchell,et al.  The hidden mental health network. Treatment of mental illness by nonpsychiatrist physicians. , 1985, Archives of general psychiatry.

[11]  L. Radloff The CES-D Scale , 1977 .

[12]  L. Ekselius,et al.  Effect on Sexual Function of Long-Term Treatment With Selective Serotonin Reuptake Inhibitors in Depressed Patients Treated in Primary Care , 2001, Journal of clinical psychopharmacology.

[13]  C. Sherbourne,et al.  The quality of care for depressive and anxiety disorders in the United States. , 2001, Archives of general psychiatry.

[14]  N. Frasure-smith,et al.  Depression and 18-month prognosis after myocardial infarction. , 1995, Circulation.

[15]  C. Hiemke,et al.  Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, Pharmacology & therapeutics.

[16]  C. Salzman,et al.  Do benzodiazepines cause depression? , 1991, Hospital & community psychiatry.

[17]  G. Klerman,et al.  Treatment received by depressed patients. , 1982, JAMA.

[18]  M. Fava,et al.  Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. , 2000, The Journal of clinical psychiatry.

[19]  R. Robinson,et al.  Depression following Myocardial Infarction , 1992, International journal of psychiatry in medicine.

[20]  R. Noyes,et al.  Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. , 1989, The Journal of clinical psychiatry.

[21]  E. Richelson Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. , 1997, Mayo Clinic proceedings.

[22]  G. Chouinard,et al.  Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. , 1999, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[23]  M. Stein,et al.  Depression in a primary care clinic: the prevalence and impact of an unrecognized disorder. , 1999, Journal of affective disorders.

[24]  M. Martens,et al.  Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[25]  R. Lipton,et al.  Headache and major depression , 2000, Neurology.

[26]  C. Carney Diabetes mellitus and major depressive disorder: An overview of prevalence, complications, and treatment , 1998, Depression and anxiety.

[27]  M. Dimatteo,et al.  Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. , 2000, Archives of internal medicine.

[28]  D A Zarin,et al.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. , 1998, JAMA.

[29]  Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina , 2002 .

[30]  S. Preskorn,et al.  Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. , 1996, Journal of clinical psychopharmacology.

[31]  J. Amsterdam,et al.  Interruption of selective serotonin reuptake inhibitor treatment , 2000, British Journal of Psychiatry.

[32]  C. Schade,et al.  A ten-year review of the validity and clinical utility of depression screening. , 1998, Psychiatric services.

[33]  P. Chue,et al.  Paroxetine: a review. , 2006, CNS drug reviews.

[34]  C. Sherbourne,et al.  Comorbid anxiety disorder and the functioning and well-being of chronically ill patients of general medical providers. , 1996, Archives of general psychiatry.

[35]  B. Rothbaum,et al.  Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. , 2001, Archives of general psychiatry.

[36]  G. Brown,et al.  Psychiatric disorder in a rural and an urban population: 3. Social integration and the morphology of affective disorder , 1984, Psychological Medicine.

[37]  M. Pollack,et al.  Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. , 2001, The Journal of clinical psychiatry.

[38]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[39]  B. Rothbaum,et al.  Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. , 2000, JAMA.

[40]  R. Hirschfeld Management of sexual side effects of antidepressant therapy. , 1999, The Journal of clinical psychiatry.

[41]  R. Hirschfeld Sexual dysfunction in depression: Disease‐ or drug‐related? , 1998, Depression and anxiety.

[42]  N. Frasure-smith,et al.  Depression following myocardial infarction. Impact on 6-month survival. , 1993, JAMA.

[43]  R. Clouse,et al.  Depression in adults with diabetes. , 1992, Diabetes care.

[44]  I. Anderson SSRIs versus tricyclic antidepressants in depressed inpatients: A meta‐analysis of efficacy and tolerability , 1998, Depression and anxiety.

[45]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[46]  C. Clary,et al.  From the Bench to the Trench: A Comparison of Sertraline Treatment of Major Depression in Clinical and Research Patient Samples. , 1999, Primary care companion to the Journal of clinical psychiatry.

[47]  L. Kirmayer,et al.  Somatization and the recognition of depression and anxiety in primary care. , 1993, The American journal of psychiatry.

[48]  N. Andreasen,et al.  Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. , 1988, The American journal of psychiatry.

[49]  R. Kessler,et al.  Posttraumatic stress disorder in the National Comorbidity Survey. , 1995, Archives of general psychiatry.

[50]  G. Brown,et al.  Types of stressful life event and the onset of anxiety and depressive disorders , 1981, Psychological Medicine.

[51]  S. Preskorn,et al.  Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. , 1996, Journal of clinical psychopharmacology.

[52]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.

[53]  E. S. Weiss,et al.  Depression and coronary heart disease: A review for cardiologists , 1997, Clinical cardiology.

[54]  R. Robinson,et al.  The neuropsychiatry of stroke. , 2000, Psychosomatics.

[55]  F. Goodwin,et al.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. , 1993, Archives of general psychiatry.

[56]  M. Olfson,et al.  Development and validation of the SDDS-PC screen for multiple mental disorders in primary care. , 1995, Archives of family medicine.

[57]  D. Gath,et al.  The Effects of Non-Prescribing of Anxiolytics in General Practice: I. Controlled Evaluation of Psychiatric and Social Outcome , 1984, British Journal of Psychiatry.

[58]  P. Silverstone,et al.  Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. , 2001, The Journal of clinical psychiatry.

[59]  R. Kessler,et al.  Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. , 1998, The British journal of psychiatry : the journal of mental science.

[60]  A. Hofman,et al.  Incidence of antidepressant drug use in older adults and association with chronic diseases; The Rotterdam Study , 1997, International clinical psychopharmacology.

[61]  L. George,et al.  Depression, disability days, and days lost from work in a prospective epidemiologic survey. , 1990, JAMA.

[62]  W. Katon,et al.  Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. , 1990, General hospital psychiatry.

[63]  R. Gorlin,et al.  The nature and course of depression following myocardial infarction. , 1989, Archives of internal medicine.

[64]  W. Katon,et al.  Depression and chronic medical illness. , 1990, The Journal of clinical psychiatry.

[65]  J. O'reardon,et al.  Depression in the medical setting: biopsychological interactions and treatment considerations. , 1999, The Journal of clinical psychiatry.

[66]  F. Nouri,et al.  Use of the Nottingham Health Profile with patients after a stroke. , 1986, Journal of epidemiology and community health.

[67]  S. Stahl,et al.  Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. , 2000, Archives of general psychiatry.

[68]  K. Krishnan,et al.  Depression in patients with coronary artery disease. , 1996, Depression.

[69]  Alan D. Lopez,et al.  Global health statistics: a compendium of incidence prevalence and mortality estimates for over 200 conditions. , 1996 .

[70]  P. Houck,et al.  Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. , 1996, The American journal of psychiatry.

[71]  J. Jefferson Antidepressants in panic disorder. , 1997, The Journal of clinical psychiatry.

[72]  R. Kessler,et al.  Lifetime panic–depression comorbidity in the National Comorbidity Survey , 2000, British Journal of Psychiatry.

[73]  M. Fava,et al.  Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. , 2000, Journal of affective disorders.

[74]  P. Lavori,et al.  Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo. , 1993, Journal of affective disorders.

[75]  M. Schroll,et al.  Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. , 1996, Circulation.

[76]  M. Fava,et al.  Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial , 1998, Biological Psychiatry.